Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Texas medical technology incubator NTEC (North Texas Enterprise Center for Medical Technology) outgrows premises:

This article was originally published in Clinica

Executive Summary

The North Texas Enterprise Center for Medical Technology (NTEC) is planning to relocate from its 11,000 square feet of donated space at Hall Office Park in the city of Frisco to a 50,000-square-foot building. "The market is ready for this kind of space," said NTEC head Larry Carlton. Builders may be ready to start within two months, reports the Dallas Business Journal. NTEC was established to help the Frisco Economic Development Corporation cultivate businesses. One of them was the biodegradable peripheral vein stent developer TissueGen, which recently raised $1.2m with which to start animal trials in June. "Early-stage companies need this infrastructure, and there's not a lot of it around," said Mr Carlton, whose new centre is planned for Eldorado Parkway/Dallas North Tollway.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT047997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel